Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APPROACH: CYB003 in Major Depressive Disorder
NCT06564818Phase 3Completed
- Sponsor
- Cybin Inc.
- Start
- Dec 2024
- Primary completion
- Sep 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of CYB003 in major depressive disorder (MDD), sponsored by Cybin Inc.. Started Dec 2024; status: completed.
02
Drugs
CYB003
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06564818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06564818.